ARIPIPRAZOLE

Post-LOESM

aripiprazole

ANDAORALSOLUTION
Approved
Oct 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of aripiprazole in schizophrenia or bipolar mania, is unclear. However, the efficacy of aripiprazole in the listed indications could be mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at…

Pharmacologic Class:

Atypical Antipsychotic

Indications (1)

Clinical Trials (5)

NCT04907279N/AUnknown

Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)

Started Nov 2021
200 enrolled
SchizophreniaSchizo Affective DisorderBipolar I Disorder
NCT04203056Phase 4Terminated

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

Started Dec 2019
NCT04030143Phase 1/2Completed

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Started Aug 2019
266 enrolled
SchizophreniaBipolar I Disorder
NCT03881449Phase 4Unknown

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

Started Apr 2019
46 enrolled
SchizophreniaMajor Depressive DisorderBi-Polar Disorder+1 more
NCT03854409Phase 1Completed

A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder

Started Jan 2019
72 enrolled
SchizophreniaBipolar I Disorder